Goldman Sachs analyst Salveen Richter raised the firm’s price target on Relay Therapeutics (RLAY) to $22 from $13 and keeps a Buy rating on the shares. Relay Therapeutics reported early Phase 1/2 results for its triplet regimen of zovegalisib, atirmociclib, and fulvestrant showing a 44% overall response rate in heavily pretreated HR+/HER2- metastatic breast cancer patients, suggesting potential for stronger outcomes in earlier-line settings, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLAY:
- Relay Therapeutics price target raised to $19 from $17 at Citizens
- Analyst Reiterates Buy on Relay Therapeutics, Citing Promising Zovega mBC Data, Favorable Safety Profile, and Phase 3 First-Line Breast Cancer Upside
- Relay Therapeutics advances zovegalisib combo in breast cancer
- Relay Therapeutics’ combination for breast cancer shows efficacy and safetyPfizer
- Relay Therapeutics initiated with a Hold at JonesResearch